Nasdaq · Healthcare
Denali Therapeutics Inc. (DNLI)
As-reported financials and recent SEC filings for Denali Therapeutics Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$0
Net income
$-512.5M
Net margin
—
Diluted EPS
$-2.97
ROE
-50.6%
P/E (TTM)
—
Market cap
$4.06B
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $330.5M | $105.1M | $48.7M |
| Gross profit | — | — | — | — | — |
| Operating income | $-555.3M | $-487.3M | $-196.7M | $-340.7M | $-295.8M |
| Net income | $-512.5M | $-422.8M | $-145.2M | $-326.0M | $-290.6M |
| Diluted EPS | $-2.97 | $-2.57 | $-1.06 | $-2.60 | $-2.39 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
8-K2026-06-18
View on EDGAR →42026-06-05
View on EDGAR →42026-06-05
View on EDGAR →42026-06-05
View on EDGAR →42026-06-05
View on EDGAR →42026-06-05
View on EDGAR →42026-06-05
View on EDGAR →42026-06-05
View on EDGAR →Go deeper on DNLI
Search Denali Therapeutics Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.